COVID-19 and the Heart

Circ Res. 2020 May 8;126(10):1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.

Abstract

Infection with the severe acute respiratory syndrome novel coronavirus produces a clinical syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 is a systemic illness characterized by hyperinflammation, cytokine storm, and elevations of cardiac injury biomarkers. Here, we review what is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects. In this rapidly moving field, this review was comprehensive as of April 3, 2020.

Keywords: biomarkers; cardiovascular diseases; coronavirus; inflammation; myocarditis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Animals
  • Betacoronavirus*
  • Biomarkers
  • COVID-19
  • COVID-19 Drug Treatment
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / therapy
  • Cell- and Tissue-Based Therapy
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / physiopathology
  • Coronavirus Infections* / therapy
  • Humans
  • Inflammation
  • Mice
  • Pandemics*
  • Peptidyl-Dipeptidase A
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / physiopathology
  • Pneumonia, Viral* / therapy
  • SARS-CoV-2

Substances

  • Biomarkers
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2